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7 ABSTRACT: Triﬂuoroacetate salt contamination of peptides represents a challenging issue related to solid phase peptide
8 synthesis and puriﬁcation because it aﬀects the chemical and biological properties of peptides. Puriﬁcation of such materials is
9 typically performed through a two-step post-synthetic procedure based on chromatography followed by ion exchange. For the
10 ﬁrst time, co-crystallization is presented in this study as a possible alternative and advantageous single-step method for the
11 obtaining of TFA-free crystals of a dipeptide. A triﬂuoroacetate-contaminated L-Leu-L-Leu dipeptide has been used for co-
12 crystallization experiments along with diﬀerent solid coformers. New multicomponent crystals containing only the title
13 compound and the second co-crystal formers are described in this work. Such results represent a novelty in the ﬁeld of peptide
14 chemistry and a valid proof for the use of crystal engineering-based method for a combined puriﬁcation and crystallization
15 strategy.
16 ■ INTRODUCTION
17 Biologics might represent the only eﬃcient way to treat some
18 speciﬁc diseases but, in many cases, the solid-state form of these
19 entities cannot be easily used in a dosage form due to their
20 questionable physiochemical properties (e.g., stability). Bio-
21 logics typically exist in the amorphous state with consequent
22 disadvantageous therapeutic and preformulation properties. A
23 possible contemporary solution to this crystallizability issue is
24 the preparation of crystal forms of these molecules using and
25 applying the concepts of crystal engineering and molecular
26 complexes.1 Hydrophobic peptides can be considered as small
27 prototypes of biologics with a nontoxic, biocompatible, and
28 ecological proﬁle. From a chemical and crystal engineering
29 point of view, their hydrophobic and hydrophilic moieties are
30 very attractive because of the possibility to generate both
31 hydrogen bonded and van der Waals interactions leading to
32 diﬀerent types of crystal packing landscapes.
33 An innovative aspect presented in this work is the use of co-
34 crystallization as an alternative method to overcome the
35 problematic removal of unwanted triﬂuoroacetic acid (TFA)
36 from a synthesized peptide. The presence of such chemical is a
37 common challenge when peptides are synthesized through solid
38 or solution phase peptide synthesis. For example, the ﬁnal step
39 in the solid phase peptide synthesis (SPPS)2 is represented by
40 the detachment of the peptide from the resin: this operation is
41 performed using a cleavage cocktail containing a large excess of
42 triﬂuoroacetic acid, a harmful and polluting strong acid, (pKa =
43 0.23), able to cleave the product from the support. TFA binds
44 to the free amino terminal as well as to any positively charged
45functionality on the side chains of the peptide generating a
46strong ion pair. Triﬂuoroacetate salts negatively aﬀect both the
47physiochemical3 and the biological4−6 properties of the
48product. For this reason, additional puriﬁcation steps through
49chromatographic techniques followed by ionic exchange
50reactions are routinely used to remove this contaminant. A
51disadvantageous loss in the yield of the peptidic material is
52unavoidable.
53To investigate the possible outcome of puriﬁcation through
54co-crystallization, a L-Leu-L-Leu dipeptide was not completely
55puriﬁed after the Fmoc SPPS: the synthesis liquor (containing
56both the product and the TFA) has been simply evaporated
57and the recovered material has been lyophilized to obtain a
58dehydrated peptide. Slow solvent evaporation experiments
59conducted by using several co-crystal formers along with the
60dipeptide product show that there is a wide range of possible
61 f1outcomes (Figure 1): this is due to the establishment of
62diﬀerential crystallization processes involving diﬀerent chemical
63species and leading to the formation of adducts with distinct
64compositions and solubilities. The novel TFA-free multi-
65component crystals presented in this paper have been obtained
66using the nonpuriﬁed Leu-Leu dipeptide and 3-amino-
67benzamide (LL:3-ABA), 1H-Pyrazole (LL:1H-Pyz), and
68methanol (LL:MeOH) conﬁrming the hypothesis of co-
69crystallization as an alternative protocol for the removal of
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70 triﬂuoroacetic acid. Crystal products containing TFA will be
71 described in a following paper7 to highlight the variety of
72 outcomes.
73 With regard to the crystal science of dipeptides, they typically
74 crystallize in multilayered structures with alternating hydro-
75 phobic and hydrophilic layers:8 the latter are represented by
76 two-dimensional sheets generated through head-to-tail hydro-
77 gen bonds involving two of the three amino H atoms and the
78 carboxylate functionality at the other terminal,9 while the third
79 one is generally involved in an interaction with an acceptor
80 contained in one of the side chains of a peptide of an adjacent
81 layer.10,11 A crystal packing problem arises when dipeptides are
82 constituted of two hydrophobic residues: from a crystallo-
83 graphic point of view, amino acids are considered hydrophobic
84 when they have no chemical functionalities involved in strong
85 hydrogen bond interactions except for the amino and
86 carboxylate groups in the polar head.12 In this case, the side-
87 chains do not contain any H-bond acceptor able to accept the
88 third H atom on the amino-terminal of the dipeptide. With the
89 exception of the L-Met-L-Met peptide (in which the third amino
90 H atom is not used for the crystal structure construction),13 the
91 hydrogen not involved in the creation of the planar sheet is
92 usually accepted by a molecule of crystallization solvent
93 included in the crystal packing.14
94 The crystal structures of L-Leu-L-Val and L-Leu-L-Leu
95 peptides represent signiﬁcant examples of such arrangements:
96 diﬀerently from other hydrophobic dipeptides, these com-
97 pounds can generate good quality large crystals (instead of thin
98 needles or plates) that can be easily analyzed. Solvates of both
99 L-Leu-L-Val with methanol (CSD refcode:15 SUWLIF), ethanol
100 (SWLOL), 2-propanol (JUCSEF01)16 and L-Leu-L-Leu with
101 isopropanol (HIQWAF),17 ethanol (JUQQUIV), propanol
102 (JUQQUB), 2-propanol (JUQQUM), a 1-propanol:2-propanol
103 mixture (JUQRAO),18 and DMSO (YORPEA)19 have already
104 been reported in the literature. The inclusion of such organic
105 solvent molecules in the crystal packing is fundamental for two
106 reasons: ﬁrst, the hydroxyl groups are involved in the hydrogen
107 bonded networks and represent a valid solution for the problem
108 related with the third amino H atom. On the other hand, these
109 solvents are contained inside channels running in the
110 hydrophobic layers: structures with such empty spaces would
111 not be stable20 and the presence of a second compound is
112 needed to ﬁll this voids, creating solid architectures. Inclusion
113 compounds of water21 (RELWIO), pyridine (YIMWOH), and
114 three diﬀerent methylpyridines22 (YIMWUN, YIMXAU,
115 YIMXEI) displaying a similar layered structure have been
116 obtained using the L-leucine tripeptide: this results conﬁrm that
117 the presence of solvents is fundamental for the crystal packing.
118Despite the importance of their role, the presence of a
119second component that is liquid at room temperature is usually
120considered a source of practical problems (e.g., molecular
121disorder, characterization issues, polymorphism). An additional
122disadvantage is the questionable stability of solvate forms. This
123aspect is vital when biological molecules are used for the
124formulation of pharmaceutical products that must maintain the
125same properties under diﬀerent environmental factors such as
126temperature, pressure, humidity, etc. Co-crystallization experi-
127ments using various solid coformers at room temperature have
128been performed to investigate the possibility to obtain similar
129stable crystal structures and to analyze the inﬂuence of these
130molecules in the packing architectures.
131Interesting cases of hydrophobic dipeptides crystallized
132without solvent or as hydrates are represented by nanotube
133formations with diﬀerent space groups and with hydro-
134phobic23−25 or hydrophilic26,27 channels. A novel structure
135(LLhex) belonging to the latter type has been obtained while
136trying to co-crystallize the title compound with 4-dimethyla-
137mino pyridine (DMAP) and will be discussed in this article.
138■ EXPERIMENTAL SECTION
139Dipeptide Synthesis. The L-Leu-L-Leu dipeptide (Figure S1) was
140synthesized through manual Fmoc solid phase peptide synthesis using
141Fmoc-NH Leu-OH protected amino acid (Merck Millipore) and 2-
142chlorotrityl chloride resin (Iris Biotech GmBH). The initial
143manufacturer loading was 1.60 mmol/g. The resin initial loading has
144been carried out using 4 equiv of protected amino acid and 8 equiv of
145N,N-diisopropylethylamine (DIPEA) in dichloromethane. The Fmoc
146deprotection steps were performed using a 20% solution of piperidine
147in dimethylformamide (DMF) while protected amino acid (4 equiv),
148HATU (4 equiv), and N,N-diisopropylethylamine (8 equiv) have been
149used for the coupling reactions in DMF; a 20:5:75 mixture of
150triﬂuoroacetic acid, triisopropylsilane, and DCM was the cleavage
151cocktail (evaporated with a rotavapor). The ﬁnal product was
152lyophilized to eliminate and avoid any possible moisture. These
153treatments lead to the elimination of most of the excess of TFA
154(boiling point: 72.4 °C) although it is still present in the ﬁnal
155compound.
156Co-Crystallization Experiments. 3-Aminobenzamide, 1H-Pyra-
157zole, Pyrazine and 4-dimethylamino pyridine were obtained from Alfa
158Aesar and used to prepare equimolar solution of dipeptide and
159coformer, using methanol (HPLC purity) as solvent. Thirty diﬀerent
160coformers have been used for a complete screening. Such molecules
161have been chosen among the most common coformers widely
162encountered, and have a wide variety of structural features (e.g., linear,
163aromatic, heterocyclic), chemical functionalities (i.e., hydrogen bond
164donors and acceptor), and chemical properties (i.e., acids and bases).
165The vials containing the ﬁltered solutions were capped with perforated
166paraﬁlm to allow slow solvent evaporation at a controlled temperature
Figure 1. Diﬀerent multicomponent systems obtained during the co-crystallization screening experiments using the TFA-contaminated L-Leu-L-Leu
dipeptide.
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Table 1. Experimental Details
(LL:3-ABA) (LL:1H-Pyz) (LL:MeOH) (LLhex)
chemical formula C12H24N2O3·C7H8N2O C12H24N2O3·C3H4N2 C12H24N2O3·1.5(CH4O) C12H24N2O3[+solvent]
Mr 380.48 312.41 292.39 244.33
crystal system, space group Monoclinic, P21 Monoclinic, P21 Monoclinic, P21 Hexagonal, P61
a (Å) 5.5139 (3) 5.3441 (2) 10.5689 (5) 23.2661 (13)
b (Å) 22.4965 (13) 13.8666 (6) 13.6495 (6) 23.2661 (13)
c (Å) 16.3133 (9) 12.1977 (5) 12.4721 (5) 5.3295 (3)
α (deg) 90 90 90 90
β (deg) 92.344 (4) 90.514 (2) 107.003 (2) 90
γ (deg) 90 90 90 120
V (Å3) 2021.9 (2) 903.87 (6) 1720.58 (13) 2498.4 (3)
Z 4 2 4 6
m (mm−1) 0.72 0.66 0.69 0.56
Crystal size (mm) 0.14 × 0.04 × 0.04 0.49 × 0.27 × 0.08 0.36 × 0.19 × 0.11 0.61 × 0.10 × 0.06
Tmin, Tmax 0.676, 0.753 0.542, 0.754 0.606, 0.753 0.531, 0.753
No. of measured reﬂections measured 14809 26545 17122 11658
No. of independent reﬂections 7019 3559 3395 2942
No. with [I > 2s(I)] 5347 3395 6054 2109
Rint 0.058 0.054 0.039 0.081
(sin q/l)max (Å
−1) 0.596 0.617 0.603 0.603
R[F2 > 2s(F2)] 0.050 0.032 0.045 0.071
wR(F2) 0.106 0.079 0.122 0.187
S 1.03 1.05 1.07 1.10
No. of reﬂections 7019 3559 6185 2942
No. of parameters 559 245 422 170
No. of restraints 17 6 11 5
Dρmax, Dρmin (e Å
−3) 0.17, −0.19 0.13, −0.16 0.27, −0.21 0.15, −0.19
Absolute structure parameter −0.06 (19) −0.07 (8) 0.10 (6) 0.1 (3)
Figure 2. Asymmetric unit of LL:3-ABA (a), LL:1h-Py (b), LL:MeOH (3), and LLhex (d).
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167 (20 °C) in an incubator. Crystals with dimensions suitable for single
168 crystal X-ray diﬀraction were collected from the solution (when
169 possible) or recovered from the dry material. The methanol solvate
170 (LL:MeOH) has been obtained when trying to co-crystallize the
171 dipeptide with pyrazine as a coformer while the hexagonal nanotube
172 structure LLhex was crystallized using a 1:1 solution with 4-
173 dimethylaminopyridine.
174 X-ray Diﬀraction. Single crystals suitable for X-ray diﬀraction
175 measurements were mounted on MiTeGen Dual-Thickness Micro-
176 Mounts and analyzed using a Bruker D8 Venture diﬀractometer with a
177 Photon detection system. Unit cell measurements and data collections
178 were performed at 173 K using a Cu Kα radiation (λ = 1.54056 Å).
t1 179 Crystal data and reﬁnement parameters are presented in Table 1.
180 Structure solutions were carried out by direct methods and reﬁnement
181 with SHELXL28 was ﬁnished using the ShelXle29 software. All non-
182 hydrogen atoms were found from electron density map and reﬁned
183 with ﬁxed bond distances and thermal parameter riding on the parent
184 atom. Highly disordered electron density inside the channel of LLhex
185 was processed using Platon Squeeze.30
186 Asymmetric Units. The asymmetric units of the four multi-
f2 187 component systems are shown in Figure 2. LL:3-ABA, LL:1H-Py, and
188 LL:MeOH crystallize in the P21 space group with a variable number of
189 components. Structures containing 3-aminobenzamide (Figure 2a)
190 and methanol (Figure 2b) are composed of two independent
191 molecules of dipeptide along with two and three molecules of co-
192 crystal former, respectively. The dipeptide molecule in LL:1H-Py
193 shows one disordered isobutyl side chain with partial occupancies of
194 83:17%; disorder has also been found in one of the methanol in
195 LL:MeOH (occupancies: 65:35%). LL:(DMAP) crystallizes in the
196 hexagonal crystal system with a P61 space group. The asymmetric unit
197 shown in the present work (Figure 2d) contains just one molecule of
198 dipeptide although additional electron density has been found inside
199 the channel: the structure was squeezed during the reﬁnement process
200 to improve the quality of the ﬁnal result.
201 The molecular conformation of the dipeptide molecules in the
202 diﬀerent structures can be described using the θ = C1
β-C1
α··· C2
α-C2
β
f3 203 torsion angle (Figure 3). This parameter is a useful descriptor of the
204 relative position of the side chains with respect to the plane generated
205 by the peptide bond in the molecule backbone. As reported by
206 Görbitz,
27 most of the dipeptides contained in the Cambridge
207 Structural Database are characterized by a |θ| > 90°: this means that
208 the side chains are usually pointing in almost opposite directions. A
f4 209 comparison of |θ| (Figure 4) of the title compounds reveal a signiﬁcant
210 diﬀerence between the here reported structures: molecules in LL:3-
211 ABA, LL:1H-Py, and LL:MeOH show values that are consistent with
212 the general tendency, while LL:(DMAP) stands out for a remarkably
213 lower angle: this represent a completely diﬀerent conformation of the
214 dipeptide with the two isobutyl chains positioned on the same side of
215 the peptide bond plane.
216■ RESULTS AND DISCUSSION
217Multilayered Structures. The dipeptides molecules in the
218structures LL:3-ABA, LL:1H-Pyz, and LL:MeOH self-
219assemble in the ac- or ab-plane to generate two-dimensional
220sheets with varying features that are related to the speciﬁc
221hydrogen bonded networks created in each structure. The two
222isobutyl side chains of each leucine residue extend in opposite
223directions above and below the plane. Neighboring sheets stack
224on top of each other creating multilayered architectures in
225which there is an alternation of hydrophilic layers represented
226by the dipeptide backbones and hydrophobic regions formed
227by the side chains of two ﬂanking sheets. The above-described
228orientation of the nonpolar side chains creates channels of
229diﬀerent sizes on both sides of each sheet: these empty spaces
230host a variable number of coformer (or solvent) molecules
231 f5(Figure 5).
232Two-Dimensional Sheets. The two-dimensional sheet of
233LL:3-ABA in the ac-plane is generated exclusively via head-to-
234tail interactions between the amino and the carboxylate groups
235of the two independent dipeptide molecules: the internal
236amidic groups of the peptide bonds are not involved in
237conventional hydrogen bonds. Only two of the three amino H
238atoms are involved in the contacts between the neighboring
239peptide molecules: the ﬁrst one creates a single H-bond with
240one of the carboxylic oxygens of a adjacent dipeptide while the
241second one forms a bifurcated contact with the COO− group of
242 f6a third molecule (Figure 6a).
243The self-assembly of the dipeptide molecules for the LL:1H-
244Pyz structure is diﬀerent in that the functionalities of the
245internal peptide bonds are involved in the formation of the
246sheet. Two of the three amino H atoms generate strong head-
247to-tail hydrogen bonds by interacting with the O− atoms of the
248C-termini of two neighboring peptides (red in Figure 6b). The
249internal peptide bond functional groups hydrogen bond with
250the charged terminals: the N−H group generates a N−H···O−
251H-bond with a carboxylate O atom (blue in Figure 6b), while
252the carbonyl acts as an acceptor for an amino H atom of a
253adjacent amino-terminal (orange in Figure 6b).
254Figure 6c shows the sheet of the LL:MeOH structure
255generated through a hydrogen bonded network that is an
256intermediate between the previous two. The amino terminals of
257the two independent dipeptide molecules in the asymmetric
258unit act as hydrogen bond donors for head-to-tail charge-
259assisted H-bonds with the carboxylate groups of the
260neighboring molecules (red contacts in Figure 6c). One of
261the two dipeptides (yellow in Figure 6c) generates the same
262interactions described for the LL:3-ABA, while the other one
263(magenta in Figure 3c) uses the N-terminus to create two
264single N−H···O− interactions with the C-terminals of two
265adjacent dipeptides. In this case just the N−H group of the
266internal peptide bond of each dipeptide participates in a N−
267H···O− hydrogen bond (blue in Figure 6c) with one of the
268carboxylate O atoms of a subsequent molecule.
269Three-Dimensional Stacking of Sheets. The channels of
270LL:3-ABA can host 2 parallel chains of coformer molecules
271 f7(Figure 7c), each one composed of only one type of the two
272molecules of coformer in the asymmetric unit: these strands are
273generated through a CO···H−N interaction between the
274amide functional groups (magenta in Figure 7c). The two
275parallel chains are connected through a weak (bond angle =
276119.30°) N−H···O hydrogen bond between the amino group
277of just one type of 3-aminobenzamide molecule and the
Figure 3. Graphical illustration of θ torsion angle in a dipeptide
molecule.
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278 carbonyl O atom of the amidic groups on the ﬂanking row
279 (orange in Figure 7c). The meta-position of the chemical
280 functionalities allows the coformers to act as cross-linkers
281 between two adjacent sheets (Figure 7b). The amino group
282 generate a NH···O− with one of the oxygen atoms of the
283 carboxylic terminal of a dipeptide molecule of one sheet, while
284 on the other side, the amidic functionality generates two
285 diﬀerent hydrogen bonds: the NH2 is involved in a NH···O
−
286 contact with one of the carboxylic O atoms of a peptide C-
287terminus and the CO acts as a hydrogen bond acceptor for
288the third amino H atom of a peptide N-terminus (the only one
289not used to generate the sheet).
290Because of the diﬀerent orientation of the dipeptide
291molecules in the sheet, the hydrophobic isobutyl chains are
292closer in LL:1H-Pyz: this generates channels of smaller size
293 f8(Figure 8a) that can host just one single row of 1H-Pyrazole
294molecules (not interacting between each other). The coformer
295contains both an acceptor (N atom) and a donor (N−H
296group) in its molecule and both are involved in the formation
297of hydrogen bonds: the acceptor generates a N···H−N+
298interaction with the amino H atom not included in the H-
299bonded network creating the sheet; the N−H functionality
300interact via single hydrogen bond with one of the O atoms of
301the C-terminus of a second adjacent dipeptide molecule
302(Figure 8b).
303The particular arrangement of the dipeptide molecules and
304the complex hydrogen bonded network in LL:MeOH implicate
305 f9a wavy conformation of the two-dimensional sheets (Figure 9a)
306with a consequent closer approach between the isobutyl side
307chains. This feature causes a reduction of the channels in the
308hydrophobic layers that, in this case, only contain few small
309molecules of crystallization solvent. Three diﬀerent molecules
310of methanol interact with the hydrophilic layers, acting as
311bridges between adjacent molecules: the disordered one (blue
312in Figure 9b) acts as both an acceptor (for a N+-H···O H-bond
313with the amino terminal of a dipeptide) and a donor (for a O−
Figure 4. |θ| torsion angle values [°] of the diﬀerent dipeptide molecules in the asymmetric units. The gray plane is the one generated by the amidic
peptide bond.
Figure 5. General packing scheme for LL:3-ABA, LL:1H-Pyz, and
LL:MeOH.
Figure 6. (a) Two-dimensional sheet of LL:3-ABA on the ac-plane. (b) Hydrogen bonded network generating the LL:1-Pyz sheet. (c) Hydrogen
bonded network generating the sheet of LL:MeOH on the ab-plane. The two independent dipeptide molecules of the asymmetric unit are shown in
diﬀerent colors. Isobutyl side chains are not shown for clarity.
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314 H···OC interaction with the carbonyl of the peptide bond of
315 a ﬂanking molecule). The other two molecules of solvent
316 cooperate tighter to create a “bridge eﬀect” between two facing
317 L-leucine-L-leucine: also in this case one of them (magenta in
318 Figure 9b) acts as both an acceptor (giving the same interaction
319 of the disordered one) and a donor (O−H···H hydrogen bond
320 with the third molecule of MeOH, green in Figure 9b), while
321 the other one (green in Figure 9b) is involved in a bifurcated
322 H···O− contact with the carboxy-terminal of a dipeptide.
323 Nanotube Structure. The crystal packing of LL:hex can be
324 included in the reported cases of nanotubes obtained using
325 hydrophobic dipeptides.27 This structure crystallizes in P61.
326The dipeptides are connected into chains by strong bifurcated
327 f10head to tail hydrogen bonds (N+-H···−O−C, red in Figure 10b)
328resulting in helices contain six molecules per turn (Figure 10a).
329Each carboxy-terminal act as a bridge connecting ﬂanking
330parallel spirals generating two interactions: a strong charge-
331assisted H-bond with the N-terminus (orange in Figure 10b),
332and another with the N−H group of the internal peptide bond
333(blue in Figure 10b). The hydrophilic channel runs along the c
334axis surrounded by hydrophobic regions represented by the
335isobutyl chains.
336A L-Leu-L-Leu dipeptide nanotube formation has already
337been reported (CSD refcode: IDUZOW)27 but this structure
Figure 7. (a) Multilayered structure generated by stacks of dipeptides sheets along the b-axis. Each channel (green) can host two coformer molecules
that act as cross-linkers between two parallel sheets (b and c).
Figure 8. (a) Stacking of sheets for LL:1H-Pyz and (b) interactions involving the coformer.
Crystal Growth & Design Article
DOI: 10.1021/acs.cgd.7b01516
Cryst. Growth Des. XXXX, XXX, XXX−XXX
F
338 crystallizes in P212121 with four molecules per turn in the
339 helices. The L-Phe-L-Phe hexagonal structure described by
340 Görbitz in the same paper (IFABEW) is highly similar to
341 LLhex (Figure S8). The hydrophilic channel is around 10 Å in
342 diameter comprising 15% of the unit cell volume and it likely
343 contains methanol and water (SI for details).
344 ■ CONCLUSION
345 The success in obtaining TFA-free multicomponent crystals
346 represents a proof of concept for the use of crystal engineering
347 as an alternative puriﬁcation method for freshly synthesized
348 peptides. Further studies aiming to probe the kinetics and
349 thermodynamics behind the diﬀerential crystallization mecha-
350 nisms are the next step. Such investigations will bring about the
351 control of the process and allow a combined puriﬁcation and
352 crystallization of biologics in a single step, saving time and
353 material.
354 In the previously reported case of studies on the
355 crystallization of hydrophobic peptides, the impact of TFA
356 was not investigated since the dimers used for the experiments
357 were obtained commercially with a high grade of purity.
358However, structures reported in the literature show the ability
359of such compounds to generate well-deﬁned crystal packings in
360which molecules of diﬀerent solvents play a fundamental role
361for the stability of the dipeptide scaﬀolding, leading to a crystal
362engineering solution.
363The structures of the present study demonstrate that the use
364of solid (at room temperature) coformers represents a valid
365alternative for the generation of crystal structures that are
366consistent with the already reported ones, in which the solvent
367molecules have been completely replaced. The comparison of
368the diﬀerent multilayered packings shows the possibility to have
369channels of variable size according to the coformers used in the
370co-crystallization experiments. In LL:3-ABA the meta-position
371of the two chemical functionalities in the 3-aminobenzamide
372molecule leads the coformer to act as a bridge connecting two
373parallel sheets, introducing an additional anchoring point in the
374multilayered stacking. This leads to 3D H-bonded architecture
375that is more stable than an assembly of 2D-sheets interacting
376through weaker interactions.
377LLhex can be included in the family of hydrophilic nanotube
378structures of hydrophobic dipeptides (also known as “the Phe-
Figure 9. (a) Multilayered stacking of LL:MeOH with molecules of solvents (b).
Figure 10. (a) Unit cell and molecular packing of LLhex. (b) Hydrogen bonded network: molecules of dipeptide belonging to the same spiral chain
are shown in diﬀerent colors. Isobutyl side chains are not shown for clarity.
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379 Phe class”31). Such self-assembling systems are considered
380 useful models from both a biological and chemical perspective.
381 On one side they can be seen as valid models for ion channels
382 or transmembrane pore assemblies.32 Also, similar microporous
383 materials attract attention and have been largely used to
384 investigate the relative sorption ability33−35 for gas storage and
385 other applications.
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